stockrow
Sunday 8 November 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.5%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
166.89
0.68
−0.41%
Follow GILD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 18.78 | 17.92 |
+8 more quarters Free account |
P/S ratio |
5.97 | 5.16 | 5.82 | 5.19 | |
P/FCF ratio |
13.43 | 12.13 | 16.92 | 16.15 | |
P/Operating CF |
36.77 | 43.95 | 68.04 | 45.89 | |
P/B ratio |
14.29 | 13.37 | 7.39 | 6.75 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.61 | 5.91 | 6.31 | 5.77 | |
EV/EBITDA |
454.36 | 687.43 | 14.30 | 13.30 | |
EV/Operating CF |
14.15 | 13.29 | 17.36 | 16.97 | |
EV/FCF |
14.87 | 13.92 | 18.34 | 17.98 | |
Quick Ratio |
0.95 | 0.75 | 1.31 | 1.06 | |
Current Ratio |
1.32 | 1.27 | 1.97 | 1.55 | |
Net Debt/EBITDA |
4.71 | (2.38) | 4.44 | 6.48 | |
Debt/Assets |
51.03% | 53.17% | 39.40% | 42.25% | |
Debt/Equity |
2.02 | 2.23 | 0.95 | 1.10 | |
Asset Turnover |
0.56 | 0.58 | 0.53 | 0.50 | |
Operating CF/Net income |
2.07 | (0.34) | 1.26 | 1.52 | |
Capex/Depreciation |
(0.32) | (0.20) | (0.17) | (0.30) | |
Interest Coverage |
12.87 | (42.08) | 10.77 | 7.81 | |
Research and Development Expense of Revenue |
19.37% | 22.61% | 19.71% | 19.97% | |
Selling, General and Administrative Expense of Revenue |
19.77% | 24.62% | 20.85% | 22.64% | |
Intangible Assets out of Total Assets |
0.42 | 0.45 | 0.44 | 0.43 | |
Share Based Compensation of Revenue |
2.82% | 2.96% | 3.13% | 2.90% | |
Graham Net Nets |
(0.12) | (0.15) | (0.08) | (0.12) | |
Graham Number |
0.00 | 0.00 | 56.12 | 52.94 | |
Earnings Yield |
(2.08%) | (2.06%) | 5.32% | 5.58% | |
Free Cash Flow Yield |
7.44% | 8.24% | 5.91% | 6.19% | |
Revenue per Share |
6.68 | 6.28 | 5.60 | 6.37 | |
Operating CF per Share |
4.05 | 2.87 | 2.05 | 2.67 | |
Capex per Share |
(0.19) | (0.11) | (0.09) | (0.16) | |
Free Cash Flow per Share |
3.86 | 2.76 | 1.95 | 2.51 | |
Cash per Share |
5.18 | 2.56 | 6.15 | 6.14 | |
Shareholders Equity per Share |
10.43 | 9.45 | 18.87 | 18.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.43 | 9.45 | 18.87 | 18.18 | |
Free Cash Flow |
4,798.00 | 3,433.00 | 2,427.00 | 3,122.00 | |
Working Capital |
3,866.00 | 2,925.00 | 9,165.00 | 6,529.00 | |
Capital Expenditures |
(237.00) | (140.00) | (117.00) | (205.00) | |
Net Current Asset Value |
(22,585.00) | (23,673.00) | (14,206.00) | (18,063.00) | |
EV/EBIT |
0.00 | 0.00 | 18.09 | 16.96 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 16.69 | 15.24 | |
| Other line items | |||||
Average Receivables |
5,051.00 | 4,918.00 | 4,564.50 | 4,666.50 | |
Average Payables |
871.00 | 628.00 | 691.00 | 774.00 | |
Average Inventory |
3,104.50 | 1,889.00 | 1,836.50 | 1,742.00 | |
Average Assets |
54,970.50 | 52,541.50 | 56,356.00 | 59,009.00 | |
Average Common Equity |
17,205.00 | 15,667.50 | 21,254.50 | 20,932.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026